Market Cap (In CAD)
224.98 Million
Revenue (In CAD)
-
Net Income (In CAD)
-78.08 Million
Avg. Volume
8221.00
- Currency
- CAD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 9.25-27.359999
- PE
- -2.16
- EPS
- -4.96
- Beta Value
- 0.885
- ISIN
- CA23256X1006
- CUSIP
- -
- CIK
- -
- Shares
- 21026400.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Douglas L. Drysdale
- Employee Count
- -
- Website
- https://www.cybin.com
- Ipo Date
- 2020-11-10
- Details
- Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
More Stocks
-
NUVSFNuVista Energy Ltd.
NUVSF
-
NGRRFNagarro SE
NGRRF
-
NIHK
-
INTEGRAENIntegra Engineering India Limited
INTEGRAEN
-
ALKEFAlkane Resources Limited
ALKEF
-
HPQFFHPQ Silicon Inc.
HPQFF
-
ACT
-
ONC